

# Kevin R Bewley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6739770/publications.pdf>

Version: 2024-02-01

39  
papers

12,907  
citations

257101

24  
h-index

276539

41  
g-index

48  
all docs

48  
docs citations

48  
times ranked

20776  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021, 397, 99-111.	6.3	3,887
2	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288.	15.2	265
3	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2021, 27, 270-278.	15.2	473
4	Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model. <i>EBioMedicine</i> , 2021, 63, 103153.	2.7	76
5	Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity. <i>Nature Communications</i> , 2021, 12, 81.	5.8	141
6	Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19. <i>Nature Communications</i> , 2021, 12, 1260.	5.8	115
7	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021, 397, 881-891.	6.3	979
8	Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays. <i>Nature Protocols</i> , 2021, 16, 3114-3140.	5.5	195
9	Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. <i>Cell</i> , 2021, 184, 2348-2361.e6.	13.5	936
10	Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. <i>Cell</i> , 2021, 184, 2201-2211.e7.	13.5	442
11	A cautionary perspective regarding the isolation and serial propagation of SARS-CoV-2 in Vero cells. <i>Npj Vaccines</i> , 2021, 6, 83.	2.9	25
12	ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models. <i>Communications Biology</i> , 2021, 4, 915.	2.0	15
13	Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using <i>In Vitro</i> and <i>In Vivo</i> Models of Q Fever. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0067321.	1.4	7
14	mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant. <i>ELife</i> , 2021, 10, .	2.8	28
15	Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques. <i>Science Advances</i> , 2021, 7, eabg7996.	4.7	20
16	Dose-Dependent Response to Infection with Ebola Virus in the Ferret Model and Evidence of Viral Evolution in the Eye. <i>Journal of Virology</i> , 2021, 95, e0083321.	1.5	6
17	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 2032-2040.	15.2	900
18	Intranasal Infection of Ferrets with SARS-CoV-2 as a Model for Asymptomatic Human Infection. <i>Viruses</i> , 2021, 13, 113.	1.5	56

#	ARTICLE	IF	CITATIONS
19	Finaxofloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever. <i>Frontiers in Microbiology</i> , 2021, 12, 760698.	1.5	5
20	Influence of Aerosol Delivered BCG Vaccination on Immunological and Disease Parameters Following SARS-CoV-2 Challenge in Rhesus Macaques. <i>Frontiers in Immunology</i> , 2021, 12, 801799.	2.2	14
21	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet, The</i> , 2020, 396, 467-478.	6.3	2,080
22	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2020, 396, 1979-1993.	6.3	1,196
23	Amplicon-Based Detection and Sequencing of SARS-CoV-2 in Nasopharyngeal Swabs from Patients With COVID-19 and Identification of Deletions in the Viral Genome That Encode Proteins Involved in Interferon Antagonism. <i>Viruses</i> , 2020, 12, 1164.	1.5	51
24	Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. <i>Cell Host and Microbe</i> , 2020, 28, 445-454.e6.	5.1	298
25	Development of a quantitative real-time RT-PCR assay that differentiates between Kyasanur Forest disease virus and Alkhurma hemorrhagic fever virus. <i>Ticks and Tick-borne Diseases</i> , 2020, 11, 101381.	1.1	1
26	Development of immunohistochemistry and in situ hybridisation for the detection of SARS-CoV and SARS-CoV-2 in formalin-fixed paraffin-embedded specimens. <i>Scientific Reports</i> , 2020, 10, 21894.	1.6	18
27	Antiviral Screening of Multiple Compounds against Ebola Virus. <i>Viruses</i> , 2016, 8, 277.	1.5	37
28	Sequence of Pathogenic Events in Cynomolgus Macaques Infected with Aerosolized Monkeypox Virus. <i>Journal of Virology</i> , 2015, 89, 4335-4344.	1.5	24
29	Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model. <i>Journal of General Virology</i> , 2015, 96, 3484-3492.	1.3	113
30	Efficacy of Liposome-Encapsulated Ciprofloxacin in a Murine Model of Q Fever. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5510-5518.	1.4	24
31	Assessment of the Protective Effect of Imvamune and Acam2000 Vaccines against Aerosolized Monkeypox Virus in Cynomolgus Macaques. <i>Journal of Virology</i> , 2013, 87, 7805-7815.	1.5	106
32	Animal models of Q fever ( <i>Coxiella burnetii</i> ). <i>Comparative Medicine</i> , 2013, 63, 469-76.	0.4	27
33	Real-time PCR system targeting a chromosomal marker specific for <i>Bacillus anthracis</i> . <i>Molecular and Cellular Probes</i> , 2008, 22, 313-315.	0.9	74
34	Nosocomial Buffalopoxvirus Infection, Karachi, Pakistan. <i>Emerging Infectious Diseases</i> , 2007, 13, 902-904.	2.0	42
35	Dengue Virus Serotype 3, Karachi, Pakistan. <i>Emerging Infectious Diseases</i> , 2007, 13, 182-183.	2.0	62
36	In vitro susceptibility of <i>Coxiella burnetii</i> to azithromycin, doxycycline, ciprofloxacin and a range of newer fluoroquinolones. <i>International Journal of Antimicrobial Agents</i> , 2004, 24, 194-195.	1.1	20

#	ARTICLE	IF	CITATIONS
37	Poliovirus type 1 in working stocks of typed human rhinoviruses. Lancet, The, 2003, 361, 1187-1188.	6.3	14
38	A black necrotic ulcer. Lancet, The, 2003, 361, 1518.	6.3	5
39	Reduced Neutralization of SARS-CoV-2 B.1.1.7 Variant from Naturally Acquired and Vaccine Induced Antibody Immunity. SSRN Electronic Journal, 0, , .	0.4	2